• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intersect ENT files for expanded Propel PMA

October 2, 2015 By Fink Densford

Intersect ENTIntersect ENT (NSDQ:XENT) said Tuesday it submitted a supplemental premarket approval application to the FDA to expand the indication on its Propel mini steroid releasing implant to cover frontal sinus surgeries.

The new indication would allow the drug-device combo to be used in the frontal sinuses, located behind the eyebrows, the Menlo Park, Calif.-based company said.

“This is an exciting milestone for Intersect ENT. More than 75,000 patients have benefitted from Propel to date and we look forward to broadening access to sustained local steroid delivery to more patients suffering from chronic sinusitis,” CEO Lisa Earnhardt said in prepared remarks.

Currently, the Propel is only indicated for placement in the ethmoid sinuses located just behind the bridge of the nose.

Earlier this week, Intersect ENT said results from 3 clinical studies of its Propel, Resolve and Nova products showed positive results. Data from the studies was presented at the American Rhinologic Society’s annual meeting in Dallas.

Each of the studies evaluated steroid releasing sinus implants placed in minimally invasive in-office procedures to reduce inflammation for patients with chronic sinusitis, the Menlo Park, Calif.-based company said.

A 20-patient study of patient-reported and endoscopic outcomes for patients treated with the company’s Propel drug-releasing implant showed a significant improvement in patient systems over 4 weeks, sustained through 12 weeks, the company said. Significant reductions in ethmoid sinus inflammation were also reported.

Filed Under: Drug-Device Combinations Tagged With: Intersect ENT Inc.

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS